Which countries will report an Andes virus case in May 2026?

Prediction market odds reflect aggregated trader expectations and can diverge from published analyst forecasts or epidemiological models. While public health agencies and research institutions may issue probabilistic assessments based on surveillance data and transmission patterns, market prices incorporate real-time information, trader conviction, and financial incentives. Analysts typically focus on biological and environmental factors, whereas markets also price in reporting delays, diagnostic capacity, and geopolitical variables. Comparing market odds to expert forecasts reveals whether traders are pricing in higher or lower risk than official guidance, offering insight into information asymmetries or market-specific dynamics around Andes virus spread.

On Kalshi, Andes virus case outcomes are priced as binary or multi-outcome contracts reflecting the probability of reported cases in specific countries by May 2026. On Kalshi, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The top outcome tracks whether a human case will be reported in the United States, currently trading at 4.0% chance. Prices move based on epidemiological updates, laboratory confirmations, and surveillance alerts from health authorities. Traders buy contracts at lower prices if they believe cases are more likely than the market implies, and sell if they expect lower probability. Volume and bid-ask spreads reflect confidence in each country outcome, with higher liquidity on geographically or epidemiologically prominent scenarios.

The market resolves on Jun 1, 2026, after the May 2026 observation period closes. Resolution is determined by official reports from public health authorities, including national health ministries, the Pan American Health Organization, and the CDC, confirming laboratory-verified human cases of Andes virus in each country. Only cases formally reported and diagnostically confirmed during May 2026 count toward resolution. The outcome depends on real-world epidemiological events and the timeliness of case detection and reporting by health systems. Markets remain open for trading until the resolution deadline, allowing participants to adjust positions as new case data emerges.

Key signals include laboratory confirmations of Andes virus in human samples, outbreak alerts from health authorities, and surveillance reports from endemic regions in South America. Rodent population surveys, environmental sampling, and occupational exposure incidents in rural or agricultural areas could increase case probability. International travel or trade events involving affected regions may shift odds for non-endemic countries like the United States. Media coverage of suspected cases, changes in diagnostic testing capacity, and WHO epidemiological updates will influence trader sentiment. Seasonal factors, climate patterns affecting rodent populations, and policy responses to emerging cases also drive market repricing toward the May 2026 resolution date.